Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia

Introduction. mBRAF mCRC has the aggressive phenotype. The incidence of such mutation in Europe and the USA is around 8–14%, in Asian countries – 4–8%. The purpose of this population-based study was to determine the incidence and identifying prognostic factors in pts with mBRAF mCRC in Russia. Mater...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: M. Yu. Fedyanin, К M. Ehlsnukaeva, I. A. Demidova, D. L. Stroyakovskiy, Yu. A. Shelygin, А. S. Tsukanov, М. V. Panina, V. Р. Shubin, F. V. Moiseenko, E. Yu. Karpenko, L. V. Bolotina, A. V. Kudryavtseva, М. L. Filipenko, I. P. Oskorbin, L. Yu. Vladimirova, N. N. Timoshkina, О. I. Kit, А. М. Stroganova, S. L. Dranko, А. I. Senderovich, А. А. Tryakin, S. А. Tjulandin
Médium: Artigo
Jazyk:Russo
Vydáno: Remedium Group LLC 2021-06-01
Edice:Медицинский совет
Témata:
colorectal cancer
mbraf
epidemiology
prognosis
free progression survival
overall survival
On-line přístup:https://www.med-sovet.pro/jour/article/view/6211
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky